You are here: Industry Insights > Novartis

News List

Novartis receives positive CHMP opinion for Rydapt cphi-online
July 25, 2017
If approved, Rydapt would represent the first targeted treatment for newly diagnosed FLT3-mutated AML in the EU.
Novartis CTL-019 unanimously passed by FDA: last mile for the marketing of the worlds’ first CAR-T en-cphi.cn
July 21, 2017
Novartis’ CAR-T therapy Tisagenlecleucel (CTL-019) evaluated by FDA is undoubtedly an important moment as there is only the final mile for the marketing of the world’s first CAR-T.
Novartis, Sanofi-backed NeuroVia closes $14M series A for X-ALD work fiercebiotech
July 21, 2017
Sanofi Genzyme and Novartis’ venture arms have backed NeuroVia, an upstart that wants to help treat the rare CNS disorder X-linked adrenoleukodystrophy.
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing worldpharmanews
July 18, 2017
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1].
FDA recommends approval for Novartis’ CTL019 to treat r/r B-cell ALL pharmaceutical-technology
July 17, 2017
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of Novartis’ CTL019 (tisagenlecleucel) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL).
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing worldpharmanews
July 17, 2017
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis.
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory commi worldpharmanews
July 13, 2017
Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy.
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory commi worldpharmanews
July 13, 2017
Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel)...
Novartis CAR-T safety in FDA spotlight pharmaphorum
July 12, 2017
FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to focus on safety concerns in the decisive meeting.
Novartis combination targeted therapy receives FDA approval europeanpharmaceuticalreview
July 10, 2017
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page